Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Update

Tenax Therapeutics, Inc. (NASDAQ:TENX) saw a significant drop in short interest in October. As of October 15th, there was short interest totalling 21,000 shares, a drop of 27.8% from the September 30th total of 29,100 shares. Based on an average daily trading volume, of 510,200 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.7% of the shares of the company are sold short.

Tenax Therapeutics Price Performance

Shares of NASDAQ:TENX traded up $0.12 during midday trading on Monday, hitting $4.87. The stock had a trading volume of 94,870 shares, compared to its average volume of 276,528. The company’s 50-day moving average price is $3.80 and its 200-day moving average price is $3.59. Tenax Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, beating the consensus estimate of ($1.99) by $0.16. On average, equities research analysts predict that Tenax Therapeutics will post -6.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on TENX. StockNews.com assumed coverage on shares of Tenax Therapeutics in a research note on Thursday, September 26th. They issued a “sell” rating on the stock. William Blair began coverage on shares of Tenax Therapeutics in a research report on Monday, September 30th. They set an “outperform” rating on the stock. Leerink Partnrs upgraded shares of Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday. Leerink Partners started coverage on Tenax Therapeutics in a research report on Thursday. They set an “outperform” rating and a $16.00 price target on the stock. Finally, Guggenheim started coverage on Tenax Therapeutics in a research note on Monday, October 14th. They set a “buy” rating and a $16.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $170.67.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.